Genetic Technologies Ltd (GENE)

$0.89

-0.01

(-0.84%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $0.88
    $0.90
    $0.89
    downward going graph

    1.18%

    Downside

    Day's Volatility :2.28%

    Upside

    1.11%

    downward going graph
  • $0.68
    $93.75
    $0.89
    downward going graph

    23.6%

    Downside

    52 Weeks Volatility :99.27%

    Upside

    99.05%

    downward going graph

Returns

PeriodGenetic Technologies LtdIndex (Russel 2000)
3 Months
-47.63%
0.0%
6 Months
-68.05%
0.0%
1 Year
-77.87%
0.0%
3 Years
-94.75%
-22.3%

Highlights

Market Capitalization
3.0M
Book Value
$0.04
Earnings Per Share (EPS)
-0.15
PEG Ratio
0.0
Wall Street Target Price
12.5
Profit Margin
-124.08%
Operating Margin TTM
-105.96%
Return On Assets TTM
-52.71%
Return On Equity TTM
-160.47%
Revenue TTM
10.2M
Revenue Per Share TTM
2.73
Quarterly Revenue Growth YOY
-2.1%
Gross Profit TTM
6.0M
EBITDA
-9.9M
Diluted Eps TTM
-0.15
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Analyst Forecast

What analysts predicted

Upside of 1304.49%

Current $0.89
Target $12.50

Company Financials

FY19Y/Y Change
Revenue
17.7K
↓ 86.56%
Net Income
-4.7M
↑ 25.06%
Net Profit Margin
-26.9K%
↓ 23968.33%
FY20Y/Y Change
Revenue
6.8K
↓ 61.23%
Net Income
-4.3M
↓ 7.74%
Net Profit Margin
-63.9K%
↓ 37054.55%
FY21Y/Y Change
Revenue
92.1K
↑ 1122.16%
Net Income
-5.5M
↑ 14.34%
Net Profit Margin
-6.0K%
↑ 57930.93%
FY22Y/Y Change
Revenue
4.8M
↑ 5536.33%
Net Income
-5.0M
↓ 1.07%
Net Profit Margin
-104.95%
↑ 5874.06%
FY23Y/Y Change
Revenue
5.8M
↑ 27.83%
Net Income
-7.9M
↑ 64.79%
Net Profit Margin
-135.28%
↓ 30.33%
FY24Y/Y Change
Revenue
7.7M
↓ 11.76%
Net Income
-12.0M
↑ 2.27%
Net Profit Margin
-156.78%
↓ 21.5%
Q4 FY22Q/Q Change
Revenue
2.8M
↑ 66.9%
Net Income
-3.7M
↑ 100.0%
Net Profit Margin
-131.45%
↓ 21.76%
Q1 FY23Q/Q Change
Revenue
1.8M
↓ 35.36%
Net Income
-2.1M
↓ 42.4%
Net Profit Margin
-117.14%
↑ 14.31%
Q2 FY23Q/Q Change
Revenue
3.0M
↑ 68.79%
Net Income
-4.2M
↑ 100.0%
Net Profit Margin
-138.8%
↓ 21.66%
Q3 FY23Q/Q Change
Revenue
2.4M
↓ 46.24%
Net Income
-3.2M
↓ 48.98%
Net Profit Margin
-131.73%
↑ 7.07%
Q4 FY23Q/Q Change
Revenue
4.0M
↑ 62.47%
Net Income
-6.4M
↑ 100.0%
Net Profit Margin
-162.16%
↓ 30.43%
Q2 FY24Q/Q Change
Revenue
3.7M
↓ 6.38%
Net Income
-5.6M
↓ 12.79%
Net Profit Margin
-151.05%
↑ 11.11%
FY19Y/Y Change
Total Assets
2.3M
↓ 47.05%
Total Liabilities
1.0M
↑ 2.73%
FY20Y/Y Change
Total Assets
10.8M
↑ 378.8%
Total Liabilities
1.8M
↑ 75.23%
FY21Y/Y Change
Total Assets
17.5M
↑ 46.94%
Total Liabilities
1.1M
↓ 45.04%
FY22Y/Y Change
Total Assets
14.6M
↓ 9.45%
Total Liabilities
3.1M
↑ 203.8%
FY23Y/Y Change
Total Assets
10.0M
↓ 28.58%
Total Liabilities
2.5M
↓ 15.49%
FY24Y/Y Change
Total Assets
6.2M
↓ 58.36%
Total Liabilities
4.4M
↑ 17.93%
Q4 FY22Q/Q Change
Total Assets
10.6M
↑ 0.0%
Total Liabilities
3.1M
↑ 0.0%
Q1 FY23Q/Q Change
Total Assets
9.9M
↓ 5.34%
Total Liabilities
2.5M
↓ 20.84%
Q2 FY23Q/Q Change
Total Assets
10.0M
↑ 0.0%
Total Liabilities
2.5M
↑ 0.0%
Q3 FY23Q/Q Change
Total Assets
8.5M
↓ 43.01%
Total Liabilities
3.7M
↓ 1.05%
Q4 FY23Q/Q Change
Total Assets
5.7M
↑ 0.0%
Total Liabilities
2.4M
↑ 0.0%
Q2 FY24Q/Q Change
Total Assets
6.2M
↓ 26.93%
Total Liabilities
4.4M
↑ 19.19%
FY19Y/Y Change
Operating Cash Flow
-4.2M
↑ 8.04%
Investing Cash Flow
-364.4K
↓ 4186.81%
Financing Cash Flow
2.2M
↓ 31477.72%
FY20Y/Y Change
Operating Cash Flow
-3.9M
↓ 5.95%
Investing Cash Flow
44.7K
↓ 112.35%
Financing Cash Flow
12.7M
↑ 487.31%
FY21Y/Y Change
Operating Cash Flow
-5.0M
↑ 14.77%
Investing Cash Flow
-571.8K
↓ 1255.64%
Financing Cash Flow
10.6M
↓ 24.05%
FY22Y/Y Change
Operating Cash Flow
-4.6M
↓ 0.06%
Investing Cash Flow
-2.4M
↑ 362.29%
Financing Cash Flow
-196.2K
↓ 102.0%
FY23Y/Y Change
Operating Cash Flow
-6.7M
↑ 51.61%
Investing Cash Flow
-209.6K
↓ 90.99%
Financing Cash Flow
4.2M
↓ 2364.71%
Q1 FY23Q/Q Change
Operating Cash Flow
-687.4K
↓ 62.22%
Investing Cash Flow
32.6K
↓ 123.83%
Financing Cash Flow
4.2M
↓ 3896.16%
Q2 FY23Q/Q Change
Operating Cash Flow
-1.8M
↑ 154.75%
Investing Cash Flow
32.8K
↑ 0.0%
Financing Cash Flow
-42.8K
↓ 101.01%

Technicals Summary

Sell

Neutral

Buy

Genetic Technologies Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Genetic Technologies Ltd
Genetic Technologies Ltd
18.39%
-68.05%
-77.87%
-94.75%
-90.68%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
1.13%
-16.13%
-1.02%
-30.71%
76.78%
Agilent Technologies Inc.
Agilent Technologies Inc.
2.42%
-8.11%
18.01%
-22.8%
84.96%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
4.08%
2.29%
14.99%
7.41%
109.35%
Danaher Corp.
Danaher Corp.
1.1%
4.75%
17.79%
-19.33%
91.02%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
5.86%
-6.0%
10.99%
-8.08%
60.05%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Genetic Technologies Ltd
Genetic Technologies Ltd
NA
NA
0.0
0.0
-1.6
-0.53
NA
0.04
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
46.49
46.49
5.05
10.51
0.63
0.23
NA
19.16
Agilent Technologies Inc.
Agilent Technologies Inc.
28.76
28.76
2.99
5.24
0.25
0.08
0.01
20.53
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.6
37.6
2.26
21.75
0.14
0.05
0.0
124.17
Danaher Corp.
Danaher Corp.
48.58
48.58
2.63
7.58
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.24
32.24
1.22
11.2
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Genetic Technologies Ltd
Genetic Technologies Ltd
NA
$3.0M
-90.68%
NA
-124.08%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$38.9B
76.78%
46.49
22.34%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$39.8B
84.96%
28.76
21.75%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$233.5B
109.35%
37.6
14.69%
Danaher Corp.
Danaher Corp.
Buy
$192.3B
91.02%
48.58
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$45.2B
60.05%
32.24
9.39%

Insights on Genetic Technologies Ltd

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 3.95M → 3.70M (in $), with an average decrease of 6.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -6.41M → -5.59M (in $), with an average increase of 14.7% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 18.0% return, outperforming this stock by 95.9%

  • Vs TMO

    In the last 3 years, Genetic Technologies Ltd has experienced a drawdown of -94.7%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 71.9%

Institutional Holdings

  • Armistice Capital, LLC

    4.16%

  • Susquehanna International Group, LLP

    1.03%

  • Morgan Stanley - Brokerage Accounts

    0.52%

  • BNP Paribas Arbitrage, SA

    0.27%

  • Rhumbline Advisers

    0.11%

  • SIMPLEX TRADING, LLC

    0.01%

Company Information

genetic technologies (asx: gtg, nasdaq global market: gene) is leading-edge genetic testing and reproductive services business which, together with an extensive range of international patents and allied research activities, aims at uncovering the impact of dna on health. throughout the asia pacific region, we translate specialised genetic tests into products and services that optimise the health knowledge and outcomes in humans, animals and plants.

Organization
Genetic Technologies Ltd
Employees
60
CEO
Mr. Simon Morriss
Industry
Health Technology

Discover More

FAQs